With regards to heart failure therapy, significantly more PPCM patients were receiving furosemide (p<0.001), angiotensin converting enzyme-inhibitor (ACE-I)/angiotensin receptor blocker (ARB) (p<0.001), β-blockers (p<0.001), spironolactone (p<0.001) and digoxin (p<0.001) compared to HHFP patients (Fig 2). The gene discussed is ACE; the disease is heart failure.